Industry Pulse
- PDF / 114,020 Bytes
- 7 Pages / 612 x 791 pts Page_size
- 71 Downloads / 208 Views
High Blood Press Cardiovasc Prev 2003; 10 (1): 57-63 1120-9879/03/0001-0057/$30.00/0 © Italian Society of Hypertension 2003. All rights reserved.
Industry Pulse Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1. Hypertension and the Metabolic Syndrome (Sponsored by Boehringer Ingelheim) . . . . . . . . . . . . . . . . . . 2. Effects of Lercanidipine on Nitric Oxide Availability (Sponsored by Innovapharma) . . . . . . . . . . . . . . . . . . 3. Search for, and Treatment of, Microalbuminuria in Patients with Hypertension (Sponsored by Sanofi-Synthelabo) 4. Ramipril Delays Progression to Heart Failure (Sponsored by Aventis) . . . . . . . . . . . . . . . . . . . . . . . . . . . 5. Renal Protection with Newer Calcium Antagonists? (Sponsored by Chiesi Farmaceutici) . . . . . . . . . . . . . . 6. Losartan Reduces the Risk of End-Stage Renal Disease in Patients with Type 2 Diabetes and Nephropathy: Evidence From the RENAAL Study (Sponsored by Merck Sharp & Dohme) . . . . . . . . . . . . . . . . . . . . . . . 7. Valsartan Beneficial for Elderly Patients with Isolated Systolic Hypertension (Sponsored by Novartis) . . . . . . . .
Abstract
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
. . . . . .
57 57 58 58 60 60
. . . . . . . . . . . . . . . .
61 62
To help the reader keep up-to-date with the very latest developments in experimental and clinical research, this section of the journal aims to provide the reader with information selected by the journal sponsors regarding emerging clinical evidence on their compounds, new areas of research interest, and any other topic which might be potentially relevant to the reader.
1. Hypertension and the Metabolic Syndrome (Sponsored by Boehringer Ingelheim)
Hypertension is one of several aspects of the so-called ‘metabolic syndrome’, a clinical entity derived from the association of insulin resistance, dyslipidaemia and hypertension. Hypertension affects 15–25% of all individuals in the industrialised world and leads to a 2- to 3-fold increased risk of cardiovascular death, and 5- to 9-times increased risk of developing type 2 diabetes mellitus. Recently, analysis of the incidence of diabetes in patients enrolled in clinical trials of antihypertensive drugs has shed some light on the possibility that these drugs may have favourable
effects on the different components of the metabolic syndrome. The metabolic effects of the blockade of the renin-angiotensinaldosterone systems are well documented in the ACE inhibitors, drugs which improve glucose metabolism in patients at high risk through their effects on cytokine and nitric oxide activity, thereby reducing the incidence of new cases of type 2 diabetes. On the other hand, angiotensin receptor blockers appear to exert a metabolic neutral effect. However, one drug belonging to this class, telmisartan, may be the exception, as it appears to activate the peroxisome proliferator activated receptor-γ (PPA
Data Loading...
